×
About 133 results

ALLMedicine™ Schnitzler Syndrome Center

Research & Reviews  44 results

Schnitzler Syndrome
https://emedicine.medscape.com/article/1050761-overview

Feb 2nd, 2023 - Practice Essentials Schnitzler syndrome is an autoinflammatory disease characterized by chronic, nonpruritic urticaria in association with monoclonal gammopathy. Associated sympoms include recurrent fever, bone pain and arthralgia or arthritis. Th...

Schnitzler Syndrome Clinical Presentation
http://emedicine.medscape.com/article/1050761-clinical

Feb 2nd, 2023 - History All patients with Schnitzler syndrome present with a chronic, recurrent, urticarial eruption. Pruritus is usually absent at the disease onset, but lesions may become mildly pruritic in approximately 45% of patients after 3-4 years. The ski...

Schnitzler Syndrome Medication
http://emedicine.medscape.com/article/1050761-medication

Feb 2nd, 2023 - Antineoplastics, Tyrosine Kinase Inhibitor Ibrutinib (Imbruvica) View full drug information Ibrutinib inhibits the function of Bruton tyrosine kinase (BTK). BTK is a key signaling molecule of the B-cell receptor-signaling complex that plays an imp...

Schnitzler Syndrome
https://emedicine.medscape.com/article/1050761-print

Feb 2nd, 2023 - Practice Essentials Schnitzler syndrome is an autoinflammatory disease characterized by chronic, nonpruritic urticaria in association with monoclonal gammopathy. Associated sympoms include recurrent fever, bone pain and arthralgia or arthritis. Th...

Schnitzler Syndrome
http://emedicine.medscape.com/article/1050761

Feb 2nd, 2023 - Practice Essentials Schnitzler syndrome is an autoinflammatory disease characterized by chronic, nonpruritic urticaria in association with monoclonal gammopathy. Associated sympoms include recurrent fever, bone pain and arthralgia or arthritis. Th...

see more →

Clinicaltrials.gov  6 results

Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
https://clinicaltrials.gov/ct2/show/NCT04213274

Dec 22nd, 2022 - The study will include a screening period (up to 28 days), a double blind, placebo controlled treatment period (14 days), followed by an 8 week safety follow up period after the second dose of study drug. Subjects with an established diagnosis of ...

Ilaris (Canakinumab) in the Schnitzler Syndrome
https://clinicaltrials.gov/ct2/show/NCT01245127

Jul 5th, 2019 - Description of the study: Objectives: Primary objective: To evaluate if canakinumab 150mg every 8 weeks can induce and maintain clinical remission in patients with the Schnitzler syndrome. Secondary objectives: To test if canakinumab 150mg can ind...

Ilaris® Effects in Schnitzler Syndrome (ILESCH)
https://clinicaltrials.gov/ct2/show/NCT01390350

Jul 17th, 2018 - This is a multi-center double-blind placebo-controlled study to assess the efficacy and safety of canakinumab (trade name Ilaris®), a high-affinity monoclonal antibody that neutralizes IL-1β, in patients with Schnitzler syndrome. Efficacy is asses...

Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors
https://clinicaltrials.gov/ct2/show/NCT00933296

Sep 8th, 2017 - The Schnitzler syndrome is a rare entity characterized by an urticarial rash and recurrent fever in a patient with a monoclonal IgM component. Other frequent signs include joint, bone and muscle pain, enlarged spleen, liver and lymph nodes, increa...

Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)
https://clinicaltrials.gov/ct2/show/NCT01045772

May 31st, 2012 - This is a single-center open label study of the IL-1 transfusion protein rilonacept in subjects with Muckle-Wells syndrome (MWS), or Schnitzler syndrome (SchS) in Germany. Prospective subjects will be recruited from a patient population previously...

see more →

News  3 results

Cracking the “MGUS” Code Reveals Monoclonal Gammopathy of Clinical Significance:
https://www.onclive.com/view/cracking-the-mgus-code-reveals-monoclonal-gammopathy-of-clinical-significance-

Nov 1st, 2022 - When assessing monoclonal gammopathy it is important to rule out clinically significant associations requiring treatment. On initial patient consultation, gathering a detailed patient history and thorough physical exam can catch clinically signifi...

Waldenstrom Macroglobulinemia Presenting With Schnitzler Syndrome
https://www.mdedge.com/fedprac/avaho/article/257527/oncology/waldenstrom-macroglobulinemia-presenting-schnitzler-syndrome
Lindsey Fitzgerald, Shashank Sama et. al.

Sep 1st, 2022 - Background Schnitzler syndrome is a rare, auto-inflammatory syndrome associated with IgM monoclonal gammopathy that manifests as a non-pruritic urticarial rash. Patients may also have intermittent fevers, lymphadenopathy, bone pain, and arthralgia.

Successful Treatment of Schnitzler Syndrome With Canakinumab
https://www.mdedge.com/dermatology/article/86939/urticaria/successful-treatment-schnitzler-syndrome-canakinumab
Robbie Pesek, MD, Roger Fox, MD

Sep 3rd, 2014 - To the Editor: Schnitzler syndrome occurs with a triad of chronic urticaria, recurring fevers, and monoclonal gammopathy. It was recognized as a clinical entity in 1972; now nearly 200 patients are reported in the medical literature.

see more →